Float Short %

6.89

Margin Of Safety %

Put/Call OI Ratio

0.26

EPS Next Q Diff

0.57

EPS Last/This Y

0.49

EPS This/Next Y

0.22

Price

1.92

Target Price

8.29

Analyst Recom

Performance Q

-63.57

Relative Volume

2.98

Beta

1.3

Ticker: ALDX

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-03-10	ALDX	6.62	0.38	0.01	29649
2025-03-11	ALDX	6.93	0.37	0.12	30318
2025-03-12	ALDX	6.99	0.36	0.68	30744
2025-03-13	ALDX	6.82	0.36	0.01	30507
2025-03-14	ALDX	6.91	0.36	0.34	30613
2025-03-17	ALDX	6.28	0.36	0.75	30993
2025-03-18	ALDX	6.68	0.37	0.37	31269
2025-03-19	ALDX	6.58	0.38	0.10	31322
2025-03-20	ALDX	6.72	0.37	0.43	31671
2025-03-21	ALDX	6.58	0.37	0.05	31751
2025-03-24	ALDX	6.61	0.40	0.25	27083
2025-03-25	ALDX	6.69	0.40	0.93	27616
2025-03-26	ALDX	6.3	0.41	0.10	28030
2025-03-27	ALDX	6.28	0.39	0.11	29338
2025-03-28	ALDX	6.68	0.38	0.20	30086
2025-03-31	ALDX	5.72	0.37	0.18	31002
2025-04-01	ALDX	5.47	0.36	0.16	32878
2025-04-02	ALDX	5.33	0.33	0.82	37613
2025-04-03	ALDX	1.45	0.37	0.55	40990
2025-04-04	ALDX	1.9	0.29	0.04	43210
2025-04-07	ALDX	1.95	0.27	0.08	45390
2025-04-08	ALDX	1.915	0.26	0.06	45732
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

22 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-03-10	ALDX	6.62	-89.3	-	-0.92
2025-03-11	ALDX	6.94	-89.3	-	-0.92
2025-03-12	ALDX	7.00	-89.3	-	-0.92
2025-03-13	ALDX	6.82	-89.3	-	-0.92
2025-03-14	ALDX	6.91	-89.3	-	-0.27
2025-03-17	ALDX	6.31	-68.6	-	-0.27
2025-03-18	ALDX	6.66	-68.6	-	-0.27
2025-03-19	ALDX	6.58	-68.6	-	-0.27
2025-03-20	ALDX	6.72	-68.6	-	-0.27
2025-03-21	ALDX	6.60	-68.6	-	-0.27
2025-03-24	ALDX	6.61	-68.6	-	-0.27
2025-03-25	ALDX	6.68	-68.6	-	-0.27
2025-03-26	ALDX	6.30	-68.6	-	-0.27
2025-03-27	ALDX	6.26	-68.6	-	-0.27
2025-03-28	ALDX	6.67	-68.6	-	-0.27
2025-03-31	ALDX	5.72	-68.6	-	-0.27
2025-04-01	ALDX	5.47	-68.6	-	-0.27
2025-04-02	ALDX	5.32	-68.6	-	-0.27
2025-04-03	ALDX	1.42	-68.6	-	-0.17
2025-04-04	ALDX	1.90	-68.6	-	-0.17
2025-04-07	ALDX	1.94	-68.6	-	-0.45
2025-04-08	ALDX	1.92	-68.6	-	-0.45
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

22 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-03-10	ALDX	0.05	6.43	6.34
2025-03-11	ALDX	0.05	6.43	6.34
2025-03-12	ALDX	0.05	6.43	6.23
2025-03-13	ALDX	0.05	6.43	6.23
2025-03-14	ALDX	0.05	6.43	6.23
2025-03-17	ALDX	0.05	6.45	6.23
2025-03-18	ALDX	0.05	6.45	6.23
2025-03-19	ALDX	0.05	6.45	6.23
2025-03-20	ALDX	0.05	6.45	6.23
2025-03-21	ALDX	0.05	6.45	6.23
2025-03-24	ALDX	0.05	6.51	6.23
2025-03-25	ALDX	0.05	6.51	6.23
2025-03-26	ALDX	0.05	6.51	6.89
2025-03-27	ALDX	0.05	6.51	6.89
2025-03-28	ALDX	0.05	6.51	6.89
2025-03-31	ALDX	0.05	6.49	6.89
2025-04-01	ALDX	0.05	6.49	6.89
2025-04-02	ALDX	0.05	6.49	6.89
2025-04-03	ALDX	0.05	6.49	6.89
2025-04-04	ALDX	0.05	6.49	6.89
2025-04-07	ALDX	0.05	6.49	6.89
2025-04-08	ALDX	-66.25	6.49	6.89
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

-0.27

Avg. EPS Est. Current Quarter

-0.24

Avg. EPS Est. Next Quarter

0.3

Insider Transactions

-66.25

Institutional Transactions

6.49

Beta

1.3

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

-90.4

Target Price

8.29

P/E

Forward P/E

PEG

P/S

P/B

1.61

P/Free Cash Flow

EPS

-0.94

Average EPS Est. Cur. Y

-0.45

EPS Next Y. (Est.)

-0.23

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

2.98

Return on Equity vs Sector %

-98.3

Return on Equity vs Industry %

-85.3

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

0.13

EBIT Estimation

Aldeyra Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 9

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

stock quote shares ALDX – Aldeyra Therapeutics, Inc. Stock Price stock today

news today ALDX – Aldeyra Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch ALDX – Aldeyra Therapeutics, Inc. yahoo finance google finance

stock history ALDX – Aldeyra Therapeutics, Inc. invest stock market

stock prices ALDX premarket after hours

ticker ALDX fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ALDX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y